NCT01516957

AMG 827 in Subjects With Psoriatic Arthritis

A Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study With an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects With Psoriatic Arthritis.

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 168 (actual)
• Sponsor: Bausch Health Americas, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Detailed description

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis. Patients will randomly receive either AMG 827 or placebo (a look-a-like liquid that does not have any drug in it) and neither the doctor nor the patient will know what treatment is being given.

Conditions

• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	AMG 827 140	140 mg AMG 827 SC (subcutaneous)
DRUG	Placebo	Placebo SC (subcutaneous)
DRUG	AMG 827 280	280 mg AMG 827 SC (subcutaneous)
DRUG	AMG 827 210	210 mg AMG 827 SC (subcutaneous)

Timeline

• Start date: 2011-10-01
• Primary completion: 2012-09-01
• Completion: 2015-09-01
• First posted: 2012-01-25
• Last updated: 2020-08-27
• Results posted: 2020-08-27

Locations

31 sites across 2 countries: United States, Canada